A new study aims to determine whether a novel drug, given alongside an established immunotherapy treatment, will improve effectiveness, help shorten the treatment period for patients and prolong the effectiveness after the treatment course is completed. Hay fever affects approximately 13 million people in the UK and current treatments, including antihistamine tablets and nasal sprays, only provide good symptom control for approximately 40% of sufferers.

 

 

Image by silviarita from Pixabay

Read more…